SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 34
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 31 32 33 34
|
presentations:
1 to
50 of
1696
|
Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV (ABSTRACT
116)
Zaayid Omar
University of Cape Town, Cape Town, South Africa
Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE (ABSTRACT
117)
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences (ABSTRACT
118)
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study (ABSTRACT
119)
Elijah R. Kakande
Infectious Disease Research Collaboration, Kampala, Uganda
Questions and Answers (Part 1)
Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results (ABSTRACT
120)
Cristina Marcelo Calvo
La Paz University Hospital, Madrid, Spain
Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV (ABSTRACT
121)
Antonio Bandala-Jacques
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS (ABSTRACT
122)
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV (ABSTRACT
123)
François-Xavier Blanc
University Hospital of Nantes, Nantes, France
Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB (ABSTRACT
124)
Phiona E. Namale
University of Cape Town, Cape Town, South Africa
Questions and Answers (Part 2)
Introduction of Speakers (Part 1)
Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation (ABSTRACT
125)
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis (ABSTRACT
126)
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris (ABSTRACT
127)
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1 (ABSTRACT
128)
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Questions and Answers (Part 1)
Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase (ABSTRACT
129)
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase (ABSTRACT
130)
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women (ABSTRACT
131)
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT (ABSTRACT
132)
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
Questions and Answers (Part 2)
Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID (ABSTRACT
108)
Meera V. Singh
University of Rochester Medical Center, Rochester, NY, USA
Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation (ABSTRACT
109)
Paraskevas Filippidis
Yale University, New Haven, CT, USA
Characterization of HIV Proviruses in Brain Microglia in PWH on ART (ABSTRACT
110)
Alana N. Thomas
National Cancer Institute at Frederick, Frederick, MD, USA
Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes (ABSTRACT
111)
Alan Winston
Imperial College London, London, UK
Questions and Answers (Part 1)
Introduction of Speakers (Part 2)
Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial (ABSTRACT
112)
Leah Rubin
The John Hopkins University, Baltimore, MD, USA
Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound (ABSTRACT
113)
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies (ABSTRACT
114)
Claudia Stroupe
Northwestern University, Chicago, IL, USA
GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa (ABSTRACT
115)
Miguel Marin
Africa Health Research Institute, Durban, South Africa
Questions and Answers (Part 2)
Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores (ABSTRACT
100)
Mamuka Kvaratskhelia
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA (ABSTRACT
101)
Hisashi Akiyama
Boston University, Boston, MA, USA
RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon (ABSTRACT
102)
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes (ABSTRACT
103)
Armando D. Mendez
Texas Biomedical Research Institute, San Antonio, TX, USA
Questions and Answers (Part 1)
Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu (ABSTRACT
104)
Guillermo Gosálbez
Ulm University Medical Center, Ulm, Germany
Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells (ABSTRACT
105)
Eli Dugan
University of California San Francisco, San Francisco, CA, USA
Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART (ABSTRACT
106)
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model (ABSTRACT
107)
Stacey A. Smith
Emory University, Atlanta, GA, USA
Questions and Answers (Part 2)
A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART (ABSTRACT
133)
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B (ABSTRACT
134)
Julia Edgar
University of Oxford, Oxford, UK
Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control (ABSTRACT
135)
Katie Fisher
Aarhus University, Aarhus, Denmark
Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART (ABSTRACT
136)
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
Questions and Answers (Part 1)
CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption (ABSTRACT
137)
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones (ABSTRACT
138)
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
|
<< first | < prev
page:
of 34
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 31 32 33 34
|
presentations:
1 to
50 of
1696
|
